Behrens v. UNITED VACCINES DIV. OF HARLAN SPRAGUE

228 F. Supp. 2d 965, 2002 U.S. Dist. LEXIS 20808, 2002 WL 31387747
CourtDistrict Court, D. Minnesota
DecidedJuly 23, 2002
DocketCiv. 00-459 (RLE)
StatusPublished
Cited by10 cases

This text of 228 F. Supp. 2d 965 (Behrens v. UNITED VACCINES DIV. OF HARLAN SPRAGUE) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Behrens v. UNITED VACCINES DIV. OF HARLAN SPRAGUE, 228 F. Supp. 2d 965, 2002 U.S. Dist. LEXIS 20808, 2002 WL 31387747 (mnd 2002).

Opinion

ORDER

ERICKSON, United States Magistrate Judge.

I. Introduction

This matter came before the undersigned United States Magistrate Judge pursuant to the consent of the parties, as *966 authorized by Title 18 U.S.C. § 636(c), upon the Motion of the Defendant United Vaccines, Inc., for a Partial Summary Judgment which seeks the dismissal of the Plaintiffs’ claim under Minnesota’s Consumer Fraud Act (“CFA”), Minnesota Statutes Section Sections 325F. 68-70, as implemented by Minnesota’s Private Attorney General Statute (“Private AG Statute”) Minnesota Statutes Section 8.31, Subdivision 3a. 1 A Hearing on the Motions was conducted on May 16, 2002, at which time, the Plaintiffs, Randy and Theresa Behrens, appeared by Todd M. Johnson, Esq., and the Defendant appeared by Timothy J. Fetterly, Esq. For reasons which follow, we grant the Defendant’s Motion.

II. Factual and Procedural History

The Plaintiffs commenced this action in February of 2000, asserting claims of strict liability, negligence, false representation, breach of express and implied warranty, and a violation of the CFA against the Defendant, based upon the alleged failure of the Defendant’s BIOCOM-DP vaccine, serial PB-13, to innoculate their mink against canine distemper. Subsequently, the Defendant brought a Motion for Summary Judgment, which urged that each of the Plaintiffs’ claims was preempted by the Viruses, Serums, Toxin, and Analogous Products Act (“VSTA”), Title 21 U.S.C. §§ 151-159. On February 22, 2002, we issued our Order, which granted the Defendant’s Motion as to the Plaintiffs’ strict liability, negligence, and breach of implied warranty claims.

In support of their claims for a breach of express warranty, for false representation, and for the purported violation of the CFA, the Plaintiffs have alleged that they had purchased the Defendant’s product in reliance upon representations made by the Defendant’s agent, to the Plaintiffs and other mink farmers, that the Defendant’s vaccine was “95 percent effective in preventing distemper in mink.” Complaint, at 2, 5. In addition, the Plaintiffs alleged that they had “purchased and used the distemper vaccine in reasonable reliance upon material representations of facts and warranties made by defendant on the package label and insert, which included representations that the distemper vaccine ‘aids in preventing distemper’ and ‘BIO-COM-DP has been demonstrated to be a safe and efficacious aid in preventing distemper.’ ” Id. at p. 2-3. We held that the portions of their claim, which were based on the labeling of the product itself, were preempted by VSTA, but those portions which were based on representations about the product’s efficacy, and which were made by the Defendant’s agent, were not preempted.

Now the Defendant has returned, seeking a Partial Summary Judgment on the Plaintiffs’ claims under the CFA, as implemented by the Private AG Statute. The Defendant contends that the Plaintiffs have not satisfied the prequisites for advancing a claim under the Private AG Stat *967 ute, because their claim fails to provide the requisite public benefit essential to such a prosecution.

III. Discussion

The Defendant argues that the Plaintiffs cannot maintain their CFA claim, or their claim for attorneys’ fees under the Private AG Statute, because a successful resolution of the Plaintiffs claim would not benefit the public, as required by the Private AG Statute. The Plaintiffs contend, however, that, since BIOCOM-DP remains on the market, the successful resolution of their CFA claim “w[ould] have a clear public benefit in halting deceptive public pronouncements and advertising regarding defendant’s product.” Memorandum of Latv in Opposition to Motion for Partial Summary Judgment, at 2. 2

A. Standard of Review. Summary Judgment is not an acceptable means of resolving triable issues, nor is it a disfavored procedural shortcut when there are no issues which require the unique proficiencies of a Jury in weighing the evidence, and in rendering credibility determinations. See, Celotex Corp. v. Catrett, 477 U.S. 317, 327, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). Summary Judgment is appropriate when we have viewed the facts, and the inferences drawn from those facts, in a light most favorable to the nonmoving party, and we have found no triable issue. See, Duffy v. McPhillips, 276 F.3d 988, 991 (8th Cir.2002); Schoolhouse Inc. v. Anderson, 275 F.3d 726, 728 (8th Cir. 2002); Krentz v. Robertson Fire Protection Dist., 228 F.3d 897, 901 (8th Cir.2000); Curry v. Crist, 226 F.3d 974, 977 (8th Cir.2000); Carter v. St. Louis Univ., 167 F.3d 398, 400 (8th Cir.1999). For these purposes, a disputed fact is “material” if it must inevitably be resolved and the resolution will determine the outcome of the case, while a dispute is “genuine” if the evidence is such that a reasonable Jury could return a Verdict for the nonmoving party. See, Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986); Herring v. Canada Life Assurance, 207 F.3d 1026 (8th Cir.2000); Austin v. Minnesota Mining and Manuf. Co., 193 F.3d 992, 995 (8th Cir.1999); Liebe v. Norton, 157 F.3d 574, 578 (8th Cir.1998); Peter v. Wedl, 155 F.3d 992, 996 (8th Cir.1998).

As Rule 56(e) makes clear, once the moving party files a properly supported Motion, the burden shifts to the nonmov-ing party to demonstrate the existence of a genuine dispute. In sustaining that burden, “an adverse party may not rest upon the mere allegations or denials of the adverse party’s pleading, but the adverse party’s response, by affidavit or as otherwise provided in this Rule, must set forth specific facts showing that there is a genuine issue for trial.” Rule 56(e), Federal Rules of Civil Procedure; see also, Anderson v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Buetow v. A.L.S. Enterprises, Inc.
888 F. Supp. 2d 956 (D. Minnesota, 2012)
Tatone v. SunTrust Mortgage, Inc.
857 F. Supp. 2d 821 (D. Minnesota, 2012)
Curtis v. Altria Group, Inc.
792 N.W.2d 836 (Court of Appeals of Minnesota, 2010)
In Re Levaquin Products Liability Litigation
752 F. Supp. 2d 1071 (D. Minnesota, 2010)
Voss v. Johnson & Johnson
752 F. Supp. 2d 1071 (D. Minnesota, 2010)
Kinetic Co. v. Medtronic, Inc.
672 F. Supp. 2d 933 (D. Minnesota, 2009)
New Hampshire Insurance v. Total Tool Supply, Inc.
621 F. Supp. 2d 121 (S.D. New York, 2009)
Kivel v. Wealthspring Mortgage Corp.
398 F. Supp. 2d 1049 (D. Minnesota, 2005)
Berczyk v. Emerson Tool Co.
291 F. Supp. 2d 1004 (D. Minnesota, 2003)
Antioch Co. v. Scrapbook Borders, Inc.
291 F. Supp. 2d 980 (D. Minnesota, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
228 F. Supp. 2d 965, 2002 U.S. Dist. LEXIS 20808, 2002 WL 31387747, Counsel Stack Legal Research, https://law.counselstack.com/opinion/behrens-v-united-vaccines-div-of-harlan-sprague-mnd-2002.